Filtry
Lessons from the 'Iressa' Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations
gefitinib, ZD1839, EGFR-TKI, NSCLC, elderly, performance status, chemonaive...
FD - Onkologie a hematologie
- 2003 •
- Jx
Rok uplatnění
Jx - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
Results of treatment with gefitinib ("Iressa",ZD1839) in 45 patients with advanced non-small-cell lung cancer
Forty-five patients with non-small-cell lung cancer underwent treatment with gefitinib; 51% of them had prior radiotherapy. Treatment duration was 1 to 14 months (median, 3 months). Diseased progressed in 18 patients within 3 months, but stabilised i...
FC - Pneumologie
- 2003 •
- D
Rok uplatnění
D - Stať ve sborníku
Gefitinib Induces Epidermal Growth Factor Receptor Dimers Which Alters the Interaction Characteristics with (125)I-EGF
The tyrosine kinase inhibitor gefitinib inhibits growth in some tumor types by targeting the epidermal growth factor receptor (EGFR). Previous studies show that the affinity of the EGF-EGFR interaction varies between hosting cell line, and that gefit...
FR - Farmakologie a lékárnická chemie
- 2011 •
- Jx •
- Odkaz
Rok uplatnění
Jx - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
Výsledek na webu
ZD 1839 (IRESSA) in treatment of patients with advanced non-small cell lung cancer (NSCLC)
Biological or targeted therapy of non-small cell lung cancer is a recent promising treatment option for pacients where standard anti-cancer drug therapy fails. The authors present their own experience with 58 patients treated in 2004-2004....
FC - Pneumologie
- 2004 •
- D
Rok uplatnění
D - Stať ve sborníku
TULUNG - Iressa: state of the registry as of 30/9/2013
The TULUNG registry is a non-interventional post-registration database focused on the collection of epidemiological and clinical data of patients with non-small cell lung carcinoma (NSCLC) who have been treated with targeted therapy in the Czech Repu...
FD - Onkologie a hematologie
- 2013 •
- Vsouhrn
Rok uplatnění
Vsouhrn - Souhrnná výzkumná zpráva
Results of gefitinib effectiveness and toxicity in non-small cell lung cancer patients within the Extended Access Program in the Czech Republic.
The study reports a retrospective analysis of safety and effectiveness of gefitinib (250 mg orally daily) administered to 809 non-small cell lung cancer (NSCLC) patients enrolled in the Czech Extended Access Program....
FC - Pneumologie
- 2009 •
- Jx
Rok uplatnění
Jx - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
Second-line treatment with gefitinib (Iressa, ZD 1839) in patient with advanced non-small-cell lung cancer.
A case is presented of a 73-year old female non-smoker with advanced, symptomatic NSCLC, initially treated with gemcitabine and carboplatin, but improved only after oral gefitinib 250mg/day, which was well tolerated and demonstrated good antitumour a...
FC - Pneumologie
- 2003 •
- D
Rok uplatnění
D - Stať ve sborníku
Analysis of patients with advanced NSCLC with long-term progression-free survival in treatment with EGFR tyrosin kinase inhibitors.
The modern treatment modalities in pneumooncology include biologically targeted therapy with tyrosin kinase inhibitors blocking activation cascade of epidermal growth factor receptor (EGFR). Erlotinib (Tarceva ?) and gefitinib (Iressa ?) are...
FD - Onkologie a hematologie
- 2011 •
- A •
- Odkaz
Rok uplatnění
A - Audiovizuální tvorba
Výsledek na webu
The importance of the relative amount of EGFR mutant cells in studied preparation for the prediction of response targeted therapy of NSCLC
Presentation: Investigation of EGFR gene mutations for prediction of response to targeted therapies tyrosine kinase inhibitors (TKI) in recent years has included as a necessary step prior to tgefitinib (Iressa) and erlotinib (Tarceva) admini...
EB - Genetika a molekulární biologie
- 2013 •
- A
Rok uplatnění
A - Audiovizuální tvorba
- 1 - 9 z 9